Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab reaches milestone from Janssen and raises FY 2013 financial guidance


Friday, 6 Dec 2013 09:59am EST 

Genmab A/S:Says has reached a new milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc., triggering a $4 million milestone.Says improves FY 2013 financial guidance.Sees FY 2013 revenue to be 645 – 670 million Danish crowns and operating result from continuing operations to be 20 – 70 million Danish crowns.Says previous guidance was FY 2013 revenue of 595 - 635 million Danish crowns and operating result from continuing operations of between negative 30 million Danish crowns and positive 35 million Danish crowns.FY 2013 revenue 599.65 million Danish crowns-Thomson Reuters I/B/E/S Estimates. 

Company Quote

221.1
5.4 +2.50%
10:59am EDT